Actively Recruiting
Evaluating FH-FOLR1 ST CAR T-Cell Therapy for Advanced or Recurrent Osteosarcoma with Prior Treatment History
Led by Fred Hutchinson Cancer Center · Updated on 2026-09-01
30
Participants Needed
1
Research Sites
782 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying FH-FOLR1 ST chimeric antigen receptor CAR T cells in patients with advanced osteosarcoma that has returned, spread, or not responded to previous treatments. This phase I trial aims to find the safest dose and evaluate side effects and how well these genetically modified immune cells work against this type of cancer. CAR T-cell therapy involves altering a patients T cells to better attack tumor cells. Participants undergo a process called leukapheresis to collect T cells, which are modified in a lab to target the FOLR1 protein on tumor cells. Before receiving the FH-FOLR1 ST CAR T cells, patients get chemotherapy with fludarabine and cyclophosphamide to prepare their bodies. The CAR T cells are then infused intravenously on day 0, 1, or 2 if no serious side effects occur. Patients may also have tumor biopsies and imaging scans such as CT, MRI, or PET during the study. During the study, participants are closely monitored with blood tests, echocardiography or MUGA scans, and imaging. Follow-up visits occur frequently for up to 28 days after infusion, then at increasing intervals for up to 13 years to assess safety, disease progression, and survival. Researchers measure treatment-related toxicities, tumor response, progression-free survival, and overall survival to understand the therapys impact.
CONDITIONS
Brief Title
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
Research Team
F
Fred Hutch Immunotherapy Intake
S
Seattle Children's Hospital Immunotherapy Intake
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here